NCT02940301 is a Phase 2 clinical trial of Ibrutinib in Classical Hodgkin Lymphoma, sponsored by Ohio State University Comprehensive Cancer Center.

Who is sponsoring NCT02940301?

NCT02940301 is sponsored by Ohio State University Comprehensive Cancer Center.

What drugs are being tested in NCT02940301?

Interventions in NCT02940301: Ibrutinib, Laboratory Biomarker Analysis, Nivolumab.

What condition does NCT02940301 study?

NCT02940301 studies Classical Hodgkin Lymphoma.

Is NCT02940301 still recruiting?

NCT02940301 is currently active, enrolled. Last updated 17 February 2026.

Last reviewed 2026-02-17 · How we verify

NCT02940301

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Ibrutinib and Nivolumab in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma

Active, enrolled Phase 2 Last updated 17 February 2026

What this trial tests

Phase 2 trial testing Ibrutinib in Classical Hodgkin Lymphoma in 18 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

20 December 2016

Primary endpoint
15 August 2026

15 August 2026

Quick facts

Lead sponsor	Ohio State University Comprehensive Cancer Center
Phase	Phase 2
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	18
Start date	20 December 2016
Primary completion	15 August 2026
Estimated completion	15 August 2026
Sites	2 locations across United States

Drugs / interventions tested

Ibrutinib (ibrutinib) — full drug profile →
Laboratory Biomarker Analysis — full drug profile →
Nivolumab (nivolumab) — full drug profile →

Conditions studied

Classical Hodgkin Lymphoma — all drugs for Classical Hodgkin Lymphoma →

Sponsor

Ohio State University Comprehensive Cancer Center

Who can join

19 and older, any sex, with Classical Hodgkin Lymphoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This phase II trial studies how well ibrutinib and nivolumab work in treating patients with classical Hodgkin lymphoma that has come back or has not responded to treatment. Ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as nivolumab, may block cancer growth in different ways by targeting certain cells. Giving ibrutinib and nivolumab may work better in treating patients with classical Hodgkin lymphoma.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Therapeutic challenges and current immunomodulatory strategies in targeting the immunosuppressive pancreatic tumor microenvironment.
Looi CK, Chung FF, Leong CO, Wong SF, et al · · 2019 · cited 131× · PMID 30987642 · DOI 10.1186/s13046-019-1153-8
Checkpoint blockade in Hodgkin and non-Hodgkin lymphoma.
Merryman RW, Armand P, Wright KT, Rodig SJ. · · 2017 · cited 87× · PMID 29296917 · DOI 10.1182/bloodadvances.2017012534
Immune checkpoint inhibitors in lymphoma: challenges and opportunities.
Hatic H, Sampat D, Goyal G. · · 2021 · cited 50× · PMID 34277837 · DOI 10.21037/atm-20-6833
Immune checkpoint blockade for hematologic malignancies: a review.
Pianko MJ, Liu Y, Bagchi S, Lesokhin AM. · · 2017 · cited 48× · PMID 28529947 · DOI 10.21037/sci.2017.03.04
The Role of Immune Checkpoint Inhibitors in Classical Hodgkin Lymphoma.
Meti N, Esfahani K, Johnson NA. · · 2018 · cited 29× · PMID 29914088 · DOI 10.3390/cancers10060204
Combination therapy with PD-1/PD-L1 blockade: An overview of ongoing clinical trials.
Johnson CB, Win SY. · · 2018 · cited 26× · PMID 29632719 · DOI 10.1080/2162402x.2017.1408744
Therapeutic Updates for Relapsed and Refractory Classical Hodgkin Lymphoma.
Voorhees TJ, Beaven AW. · · 2020 · cited 25× · PMID 33050054 · DOI 10.3390/cancers12102887
Immunotherapy of Lymphoma and Myeloma: Facts and Hopes.
Pianko MJ, Moskowitz AJ, Lesokhin AM. · · 2018 · cited 25× · PMID 28899972 · DOI 10.1158/1078-0432.ccr-17-0539

Verify or expand the search:

Other trials of Ibrutinib

Trials testing the same drug.

NCT07377578 — A Study of Rocbrutinib Versus Investigator's Choice of BTK Inhibitors in Patients With Relapsed or Refractory Mantle Cel · Phase 3 · recruiting
NCT07052695 — Mosunetuzumab for CLL MRD Clearance · Phase 1, PHASE2 · recruiting
NCT06649812 — Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggress · Phase 2 · recruiting
NCT07169565 — Ibrutinib Followed by BR (Bendamustine and Rituximab) as a Time-Limited Therapy for Waldenström Macroglobulinemia · Phase 1 · not yet recruiting
NCT06357676 — Glofitamab Plus Ibrutinib With Obinutuzumab for the Treatment of Patients With Mantle Cell Lymphoma, IGNITE MCL Trial · Phase 1, PHASE2 · recruiting

Other recruiting trials for Classical Hodgkin Lymphoma

Currently open trials in the same condition.

NCT06870487 — A Study to Learn About the Study Medicine Called PF-08046032 in People With Advanced Cancers · Phase 1 · active not recruiting
NCT06848569 — Sintilimab Plus AVD in Pediatric Low/Moderate Risk Hodgkin Lymphoma: A Phase II Study · Phase 2 · recruiting
NCT06563245 — Brentuximab Vedotin for Newly Diagnosed cHL in Chinese CAYA Based on PET/CT Assessment · Phase 2, PHASE3 · recruiting
NCT05934084 — Lifestyles Implemented-Survivorship Care Plan In Lymphoma Survivors · NA · recruiting
NCT05900765 — A Study of Zimberelimab(GLS-010) Combined With AVD for Newly Diagnosed Early-stage Hodgkin's Lymphoma · Phase 2 · recruiting

Other Ohio State University Comprehensive Cancer Center trials

Trials by the same sponsor.

NCT06816979 — Lumbar Punctures for the Detection of ctDNA in the Cerebrospinal Fluid of Patients With Stage III and IV Non-Small Cell · NA · not yet recruiting
NCT07529483 — Endoscopic Ultrasound-Guided Chemoablation for the Treatment of Pancreatic Cysts · Phase 2 · not yet recruiting
NCT07455513 — A Novel Tobacco Cessation Resource for Smokers With a Diagnosed or Suspected Thoracic Cancer · NA · not yet recruiting
NCT07217990 — Neoadjuvant Complete Response Customized Treatment Approach for Definitive Management of Breast Cancer · Phase 1, PHASE2 · not yet recruiting
NCT07503925 — THRIVE Study: Understanding How Oral Nicotine Pouches Affect Public Health · Phase 4 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02940301 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Ohio State University Comprehensive Cancer Center
Last refreshed: 17 February 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02940301.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing